
|Videos|November 11, 2016
Current Progress and Future With Glembatumumab Vedotin in TNBC
Author(s)Linda T. Vehdat, MD, PhD
Linda T. Vahdat, MD, PhD, Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the current progress being made with glembatumumab vedotin in triple-negative breast cancer (TNBC) and what the future holds for this agent.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
2
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
3
Five-Year CAR T Data Reflect Long-Term PFS in Multiple Myeloma
4
MB-105 Gains FDA RMAT Designation in R/R T-Cell Lymphoma
5









































